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ABSTRACT
Objective To characterise the phenotypes associated
with the p.A16V mutation of PRSS1.
Design Clinical and epidemiological data were collected
for any family in which a p.A16V mutation was identified,
either referred directly to the European Registry of
Hereditary Pancreatitis and Familial Pancreatic Cancer or
via a collaborator. DNA samples were tested for
mutations in PRSS1, SPINK1, CFTR and CTRC.
Patients Participants were recruited on the basis of
either family history of pancreatitis (acute or chronic) or
the results of genetic testing. Families were categorised
as having hereditary pancreatitis (HP), idiopathic disease
or pancreatitis in a single generation. HP was defined as
$2 cases in $2 generations.
Main outcome measures Onset of painful episodes of
pancreatitis, death from pancreatic cancer, diagnosis of
diabetes mellitus and exocrine pancreatic failure.
Results Ten families with p.A16V mutations were
identified (22 affected individuals): six HP families, three
with idiopathic disease and one with only a single
generation affected. The median age of onset, ignoring
non-penetrants, was 10 years (95% CI 5 to 25). There
were eight confirmed cases of exocrine failure, four of
whom also had diabetes mellitus. There were three
pancreatic cancer cases. Two of these were confirmed as
p.A16V carriers, only one of whom was affected by
pancreatitis. Those with p.A16V pancreatitis were
compared to affected individuals with p.R122H, p.N29I
and no PRSS1 mutation. No significant differences were
proven using logrank or ManneWhitney U tests.
Conclusions Penetrance of p.A16V is highly variable
and family dependent, suggesting it contributes to
multigenic inheritance of a predisposition to pancreatitis.
BACKGROUND
Hereditary pancreatitis (HP) is an autosomal
dominant disease with penetrance that has been
calculated to be as high as 93%.1 HP is characterised
by frequent attacks of epigastric pain, normally
associated with nausea and vomiting. Symptoms
may start shortly after birth, but onset varies
greatly, with some individuals not exhibiting
symptoms until adulthood.2 There is usually
progression to chronic pancreatitis with endocrine
and exocrine failure and an increased risk of
pancreatic cancer.1e3 The natural history of HP
follows a similar pattern to chronic pancreatitis
associated with alcohol, but there are important
differences: HP has an earlier age of onset of
pancreatitis, but malabsorption and diabetes
mellitus occur at a later stage in the disease.2 4 5
Causative mutations have been discovered in the
cationic trypsinogen gene, PRSS1 at bases 365 and
86 of the cDNA (c.365G/A6 and c.86A/T7).
These are now known as p.R122H6 and p.N29I,7
respectively, according to the amino acid substitu-
tion and position in the protein sequence. These
mutations are rarely identiﬁed in general screens of
patients with idiopathic disease.8 9 The phenotype
of p.R122H and p.N29I has been well charac-
terised,1 2 but there are many other rare mutations
or polymorphisms of PRSS1 that are less well
understood.10
p.A16V is the third most common PRSS1 muta-
tion and is signiﬁcantly associated with pancrea-
titis.11 It was ﬁrst identiﬁed in pancreatitics with no
family history11 and has subsequently been reported
by other groups in apparently idiopathic patients.8
It is relatively rare in families with multiple cases of
pancreatitis.2 8 11 In contrast, rare instances of p.
R122H in individuals without a family history may
be explained by either a limited pedigree or by
spontaneous mutation.12 This is the ﬁrst study that
attempts to characterise the clinical signiﬁcance of
p.A16V and is the largest series published to date.
A number of registries have been established to
investigate both the phenotype and genotype of HP
and the potential for new therapies. The European
Registry of Hereditary Pancreatitis and Familial
Pancreatic Cancer (EUROPAC) was established in
1997 and has a network of collaborating clinicians
and scientists. Families are deﬁned as having HP if
the inheritance is consistent with highly penetrant
autosomal dominance. This usually requires at least
two ﬁrst degree relatives with pancreatitis in
multiple generations, although in some cases three
or more second degree relatives may be adequate
evidence.2 The PRSS1 gene is tested in a consenting
affected individual from each family. Due to the fact
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that families are registered before full examination of the family
tree, some individuals have been included who are subsequently
shown to have no family history of pancreatitis. Other families
are included on the registry where there are two or more cases,
but where the pattern of inheritance is inconsistent with highly
penetrant autosomal dominance. These families have previously
been described as having familial idiopathic pancreatitis (FIP).13
FIP families have a very high incidence of the p.N34S mutation in
the SPINK1 gene, this mutation corresponds to a change at
position 101 of the cDNA (c.101A/G) and is in linkage
disequilibrium with a series of other changes, none of which
(including p.N34S) have a known functional consequence.14
These FIP families do not have the p.R122H or p.N29I mutations
of PRSS1.13
In 1999 Witt et al11 published a paper detailing the results of
genetic testing of children with chronic pancreatitis. Of the 44
children tested, 30 had apparent sporadic disease with a further
14 having a family history. Of the 30 sporadic cases, p.A16V was
detected in three individuals. It was also detected in one indi-
vidual with a family history. One p.R122H mutation was also
detected in the family history group. Further individuals from
families with p.A16Vwere tested for the mutation, with just one
of seven carriers being affected. This suggested that p.A16V is
a low penetrance mutation, although the numbers involved were
too low for ﬁrm conclusions.
In this paper a range of phenotypes will be described for the p.
A16V mutation and we will discuss why p.A16V differs from
the true HP mutations.
METHODS
Recruitment
Most kindreds were directly recruited and characterised by
EUROPAC on the basis of presumed family history, but four
families with known p.A16V mutations were referred as a result
of this study being instigated. The ﬁrst p.A16V family recruited
by EUROPAC was identiﬁed as having an abnormal cluster of
pancreatitis in 1998, but was only tested for p.A16V after the
discovery of the mutation by Witt et al in 1999.11 Five other
families with a p.A16V mutation were recruited between 1999
and 2007. In addition, the registry became aware of one family
with multiple cases, and two individuals with no known family
history after clinicians contacted us for advice. No data from
these families were included in any analysis as we were unable to
conﬁrm patient consent.
The registry obtained multi-centre research ethics committee
approval to register participants and test their DNA for varia-
tions associated with pancreatitis. Recruitment was via the
individual’s specialist, family doctor or direct contact with the
study co-ordinator. The ﬁrst individual identiﬁed within a regis-
tered family was labelled as the proband. Affected probands or
the closest relative to unaffected probands were taken as the
index case. They were sent a patient information sheet and,
following a suitable interval, gave written informed consent.
Data collection
Data were collected by a series of questionnaires supported by
clinical consultations. DNA was collected and stored in
compliance with the Human Tissue Act 2004 (England and
Wales) under the care of the Mersey Regional Genetics Service.
The data were used to build a family tree using Progeny software
(v 7.01) and further members of the family were approached via
the proband as appropriate, with data and DNA obtained from
consenting individuals. The implications of testing were
discussed with the participant before it was performed. Typi-
cally, all individuals had PRSS1 analysis, which involved
sequencing of exons 2 and 3 to identify commonmutations and if
none were detected, sequencing of all exons. In idiopathic cases
and p.A16V carriers, PRSS1 sequencing was supplemented by
testing for mutations in the SPINK1 (PSTI) and the cystic ﬁbrosis
transmembrane receptor (CFTR) genes. Exon 3 of SPINK1 was
sequenced to identify any possible p.N34S mutations and CFTR
was tested in all cases for p.DF508, p.G542X, p.N1303K, p.
R117H, 621+1 G-T, 1898+1GA, p.W1282X and p.G551D and in
some cases with an additional 24 markers according to the
recommendations of the American College of Medical Genetics
(ACMG) and the American College of Obstetricians and
Gynaecologists (ACOG).15 In this study affected p.A16V carriers
were also tested for mutations in CTRC exons 2, 3 and 7.
Mersey Regional Genetics Service used ﬂuorescent sequence
analysis to identify PRSS1 mutations. This involved the use of
nested PCR facilitated by uniseq tagged primers. Some of the
testing performed in the families included in this paper was
conducted at collaborating centres.
Categorisation of families
After families had been fully investigated, there was a multi-
disciplinary discussion by a group of clinicians and scientists.
Families were designated as HP, single generation, or idiopathic.
Idiopathic disease was deﬁned as the presence of pancreatitis in
the absence of a known aetiology or family history.
Statistical analysis
Data from the EUROPAC registry were analysed using StatView
v 5.0. Endpoints including onset of pancreatitis and diagnosis of
endocrine and exocrine pancreatic failure were analysed using
the method of KaplaneMeier and differences assessed using the
ManteleCox logrank test. For patients where an end point was
not reached, censor times were the age of last contact. Differ-
ences in median values for continuous data were tested using the
KruskaleWallis (for comparison of multiple groups) and
ManneWhitney U (for comparison of two groups) tests.
RESULTS
Identification of p.A16V in EUROPAC families
A summary of families registered on the EUROPAC database in
January 2009 is shown in table 1. This shows the prevalence of
the p.A16V compared to the other mutation groups.
Nine of the ten p.A16V families originated from Western
Europe (the UK and Ireland, Scandinavia, Belgium, France and
Switzerland), with the ﬁnal family being from the USA. A
sample family from each group is shown in ﬁgure 1.
The variable phenotype of p.A16V families
Of the 10 different families with positive test results for a p.A16V
mutation, six met the criteria for classiﬁcation as having HP and
three as having idiopathic disease, while one had multiple cases
but only in a single generation. Of these families, three of the HP
kindreds, two from the idiopathic group and the FIP family have
been previously reported.1 2
Family A is an example of a kindred described as having HP
(ﬁgure 1A); as with all such families the deﬁnition of HP was
based on the phenotype and preceded genetic testing. All families
in this group were deﬁned as having HP regardless of whether
mutations were detected. In this case the family was identiﬁed
after the proband’s children (individuals 3 and 5) were affected by
pancreatitis. Both p.R122H and p.N29I were excluded and a p.
A16V mutation in one copy of PRSS1 was detected in the
proband (individual 1). She was also tested for the p.N34S
358 Gut 2010;59:357e363. doi:10.1136/gut.2009.186817
Pancreas
group.bmj.com on January 26, 2017 - Published by http://gut.bmj.com/Downloaded from 
mutation in SPINK1, 32 mutations in CFTR and mutations in
exons 2, 3 and 7 of CTRC; none of these genes were mutated.
Mutations in modiﬁer genes (CTRC, SPINK1 and CFTR) were
not detected in any of the HP families, although a previously
reported polymorphism (c.180C/T, p.G60G)16 was seen in two
of six of these families (families C and E). This polymorphism has
been previously reported in 21% of control samples16 and is
therefore clearly not over-represented in our cohort.
In this report ‘affected’ has been taken to mean that individuals
have reported symptoms of pancreatitis, so the possibility of sub-
clinical disease cannot be excluded in other family members. In
family A one of the proband’s siblings has diabetes (individual 8).
This could be a manifestation of pancreatic inﬂammation in the
absence of pain. This individual does not carry p.A16V. It is possible
that, at least in this kindred, p.A16V is modifying the symptoms of
an underlying inherited pancreatic disease, with the mutation
increasing the chance of pain. However, as diabetes mellitus is not
uncommon, the cases in such families may well be coincidental.
p.A16V could explain the pancreatitis in all the p.A16V HP
kindreds, but even in these families, not all carriers had explicit
symptoms. Unavoidably, most unaffected individuals in the fami-
lies were not tested. Of 23 individuals who were conﬁrmed to have
the p.A16V mutation, only 15 had reported symptoms of pancre-
atitis. All of the proband’s siblings in family A were tested for p.
A16V; three (individuals 9e11) carried the mutation but none
reported symptoms. The proband’s mother was tested and no
mutation was detected, indicating that the mutation was inherited
from the father (individual 7). There were no cases of pancreatitis in
any of his eight siblings, although three were affected by diabetes
mellitus. No testing was conducted within this generation. Two of
the siblings with diabetes were identical twins, consistent with
a genetic predisposition to diabetes in this part of the kindred. Note
however, that if the risk of diabetes is independent of the p.A16V
mutation and the inherited risk accounts for the diabetes seen in
individual 8, then the father of the proband (individual 7) must have
carried both the p.A16Vmutation and the predisposition to diabetes
without developing symptoms.
The EUROPAC database has registered 142 families who have
been classiﬁed as having idiopathic disease and three of these
have a proven p.A16V mutation (2.1%). The families are named
G (ﬁgure 1B), H and I (family trees not shown). In all cases,
referral was atypical for EUROPAC, in that there was no family
history. Unlike any of the HP families, genetic testing was
performed before recruitment to the study. For example, family G
(ﬁgure 1B), was referred after an 11-year-old boy (individual 1)
was admitted to hospital with recurrent abdominal pain which
had ﬁrst started at the age of 5. An appendicectomy was
performed, but histology showed no evidence of inﬂammation.
The patient subsequently developed a pancreato-pleural ﬁstula
requiring a chest drain. Due to his personal history, his clinicians
requested testing for a PRSS1 mutation. Subsequent to disco-
very of a p.A16Vmutation, his mother and brother (individuals 3
and 4) underwent testing and have been conﬁrmed as unaffected
p.A16V carriers. Neither of the proband’s maternal grandparents
(individuals 8 and 9) are affected and testing has not been
performed in either case. Similarly in families H and I, there was
childhood onset disease, consistent with the original identiﬁca-
tion of p.A16V in sporadic cases identiﬁed in paediatric units.11
This may represent a referral bias rather than a feature of p.A16V
per se. No modiﬁer gene mutations were detected in any of these
families, although the p.G60G polymorphism of CTRC was
observed in the affected individual of family I.
HP is deﬁned as an autosomal dominant disease and
EUROPAC requires evidence for such transmission before clas-
sifying a family in this group. There are 40 pancreatitis families
on the registry in whom despite thorough investigation, the
disease appears to be limited to a single generation with no
evidence for spontaneous mutation. This phenotype is consis-
tent with a multigene or recessive syndrome. One of these 40
families, family J (ﬁgure 1C), carries an p.A16V mutation (2.5%).
This family was referred after pancreatitis was diagnosed in four
of eight siblings, one of whom had already died from a histolog-
ically proven adenocarcinoma of the pancreas at the age of 44.
The other affected siblings all tested positive for the p.A16V
mutation. Only one affected individual was tested in this family
for modiﬁer gene mutations. This individual was homozygous
for the p.G60G polymorphism of CTRC but had no other varia-
tion. The remaining four siblings were unaffected and declined
genetic testing. The individual with pancreatic cancer was not
tested for p.A16Valthough she had been affected by pancreatitis
prior to developing malignancy. Both the parents and offspring
were asymptomatic and testing was not performed in either the
preceding or subsequent generation.
Phenotype of p.A16V families compared to carriers of other
PRSS1 mutations
A visual comparison of pedigrees indicates that there are differ-
ences between the phenotype of p.A16V and the phenotype
associated with other PRSS1 mutations. However, the low
incidence of p.A16V and the even smaller numbers of carriers
affected by diabetes mellitus, malabsorption or pancreatic cancer
means that there is insufﬁcient power for a meaningful statistical
analysis. Nevertheless, the data summarised in table 2 conﬁrm
that cancer and both endocrine and exocrine failure are features
that occur within p.A16V families. To further illustrate the level
of risk, survival curves were producedwhich are shown in ﬁgure 2.
For all end points, Neg All HP is signiﬁcantly different from the
two groups with known HP mutations (p.R122H and p.N29I).
These differences have already been described and discussed
elsewhere.1 2 There are too few data to prove differences between
p.A16V and the other groups, but the survival curves illustrate
Table 1 Summary of mutations present within EUROPAC pancreatitis
families who have undergone genetic testing, January 2009
Mutation Families Affected
Total pancreatic
cancer cases
(in affected
individuals)
Total HP 149 652 45 (37)
p.R122H 71 336 19 (16)
p.N29I 32 157 10 (10)
Neg All 37 134 13 (10)
Other mutation 3 10 1 (1)
p.A16V (HP) 6 15 2 (0)
Total idiopathic 142 142 16 (0)
No PRSS1 mutation 139 139 16 (0)
p.A16V (single case) 3 3 0 (0)
Total single generation 40 89 7 (2)
No PRSS1 mutation 39 85 6 (1)
p.A16V (single generation) 1 4 1 (1)
Overall total 331 883 68 (39)
HP, hereditary pancreatitis. ‘Affected’ refers to individuals with pancreatitis (acute or
chronic). The total number of pancreatic cancer cases is given; values in brackets represent
cancer cases in affected individuals. Values are broken down for each mutation. ‘Neg All’
means that the phenotype is consistent with HP but none of the known mutations have been
identified in affected individuals. ‘Other mutation‘ includes families with rare but known
PRSS1 mutations, eg p.R122C and p.V39A. ‘Single generation’ means there are multiple
cases of pancreatitis within kindreds but no evidence of autosomal dominant inheritance.
‘p.A16V (single generation)’ refers to the one family with a p.A16V mutation that displays
this phenotype. The idiopathic pancreatitis group includes three families who have a proven
p.A16V mutation but only one case of pancreatitis.
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Figure 1 Sample pedigrees indicating the variable phenotype of p.A16V. Ages and unique personal identification numbers are shown below each
family member followed by a description of the type of p.A16V test. Arrows indicate index cases. A shaded left upper quadrant indicates that the
individual is affected by pancreatitis, shading of the left lower quadrant indicates diabetes mellitus, and a shaded right lower quadrant indicates exocrine
pancreatic failure. The presence of a dot in the right upper quadrant signifies the presence of a p.A16V mutation, while individuals assumed not to have
a p.A16V mutation are described as off kindred and are marked with a cross. The central black circle indicates the presence of a confirmed pancreatic
adenocarcinoma. (A) Displays autosomal dominant inheritance. (B) Includes an idiopathic case of pancreatitis. (C) Defined as having familial idiopathic
pancreatitis as cases of pancreatitis, diabetes and pancreatic cancer are restricted to a single generation.
Table 2 Summary of EUROPAC p.A16V families, January 2009
Family Classification
Number testing
positive
for p.A16V*
(with pancreatitis)
Median age
of onset (IQR) (years)
(all patients
testing positive
for p.A16V*)
Median age of
onset (IQR) (years)
(patients with
pancreatitis)
Endocrine
pancreatic failure
(with pancreatitis)
Exocrine
pancreatic failure
(with pancreatitis)
Pancreatic
cancer cases
(with pancreatitis)
A HP 7 (3) 18 (7e53) 10 (5e21) 4 (0)y 1 (1) 0
B HP 2 (2) 2 (1) 2 (2) 0
C HP 2 (2) 0 0 0
D HP 4 (4) 0 0 0
E HP 5 (2) 0 0 1 (0)
F HP 3 (2) 2 (2) 2 (2) 1 (0)
G Idiopathic 3 (1) Not reached
(5enot reached)
2 (1e5) 1 (0)y 0 0
H Idiopathic 3 (1) 1 (1) 1 (1) 0
I Idiopathic 4 (1) 0 0 0
J Single generation 4 (4) 27 (25e28) 27 (25e28) 0 2 (2) 1 (1)
Totals 37 (22) 26 (7e54) 10 (5e26) 10 (4) 8 (8) 3 (1)
HP, hereditary pancreatitis; IQR, interquartile range.
*Including deduced carriers.
yIncluding one case confirmed not to have the p.A16V mutation.
Each p.A16V family is described including the number of individuals with symptomatic pancreatitis. The median age of onset of pancreatitis is derived using the method of KaplaneMeier. Median
age of onset is given for all patients with pancreatitis or for all patients with p.A16V mutations (censoring at age of last contact for unaffected individuals). IQR is the age of 25% incidence to the
age of 75% incidence. The numbers of individuals diagnosed with diabetes, malabsorption or pancreatic cancer are also given. Of the HP families without p.A16V, 58 p.R122H, 24 p.N29I, 21 Neg
All and 2 with other mutations have been previously reported. In addition, 115 idiopathic cases have been reported previously. Of the p.A16V families, three of the HP kindreds, two from the
idiopathic group and the family with multiple cases in a single generation have been previously reported.1 2 13
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possible trends. To simplify analysis and increase power, the two
mutation groups (p.R122H and p.N29I) were combined and will
be described as the ‘mutation group’ in contrast to the Neg All
HP group.
The age of diagnosis of diabetes appears similar in the p.A16V
and Neg All HP groups (logrank p value for p.A16V compared
to the combined mutation group was 0.076, with a p value for
p.A16V compared to the Neg All HP group of 0.83). In contrast,
when looking at age of diagnosis of exocrine pancreatic failure,
the p.A16V is more like the mutation group than the Neg All HP
group (logrank p value for p.A16V compared to the Neg All HP
group is 0.087 with a p value for p.A16V compared to the
combined mutation group of 0.88). There is the suggestion that
the age of onset of pancreatitis in p.A16V appears later than
with the mutation group and is more like the Neg All HP group
than either p.R122H or p.N29I (logrank p value for p.A16V
compared to the combined mutation group is 0.080, c21¼3.06,
contrasting with a p value for p.A16V compared to the Neg All
HP group of 0.18).
Penetrance
An exact calculation of penetrance is difﬁcult to perform as
individuals who are not affected are often reluctant to agree to
genetic testing. Taking family A (ﬁgure 1A) as an example, the
oldest age of onset was 16 and four out of the seven known
carriers were unaffected (at least until the age of 40). On this
basis, penetrance can be estimated at 43% in this family.
However, half of the proband’s paternal antecedents would be
expected to be carriers. As none were reported to be affected, the
actual penetrance of p.A16V in this kindred is probably far lower.
An alternative approach is to take a family member affected
by pancreatitis and see how many ﬁrst degree relatives they have
who are also affected. Assuming an autosomal dominant pattern
of inheritance, each ﬁrst degree relative of an affected individual
has a 50% chance of being a mutation carrier. The index case in
each family can be identiﬁed and the proportion of affected ﬁrst
degree relatives calculated; doubling this ﬁgure gives an estimate
of penetrance. This was performed blind to any mutation
analysis using all families on the EUROPAC registry with the
results shown in table 3.
The analysis is subject to ascertainment bias. Families with
greater numbers of cases are more likely to be recruited.
Furthermore, in families with variable penetrance, an index case
is more likely to be in a section of the family with the greatest
number of affected individuals. On the other hand, this
approach also means that one affected carrier is always omitted
from the calculation (the index case). In ﬁgure 3, the penetrance
for individual families is represented in a box plot. Krus-
kaleWallis testing of the medians showed a signiﬁcant difference
across the ﬁve groups with a p value of 0.02, although p.A16V
Figure 2 KaplaneMeier curves comparing p.A16V to other mutation groups. Inverted KaplaneMeier curves are shown for three different endpoints:
(A) onset of pancreatitis symptoms; (B) diagnosis of diabetes mellitus; and (C) diagnosis with exocrine failure. Confidence intervals are shown in grey,
with those for the p.A16V group in a darker shade. The wide CIs in the p.A16V group are due to the low data volume, which is also indicated by the
number of at risk individuals shown below each graph.
Table 3 Estimate of penetrance in pancreatitis families
Mutation
First degree relatives
of the index case
First degree relatives
affected by pancreatitis
Estimated penetrance
(if 50% of first degree
relatives are carriers)
p.R122H 448 157 (35.0%) 70%
p.N29I 189 57 (30.2%) 60.4%
Neg All HP 210 66 (31.4%) 62.8%
Single generation
(excluding p.A16V)
218 43 (19.7%) 39.4%
p.A16V (all groups) 62 14 (21.9%) 43.8%
A summary of the total number of first degree relatives of the index case in each mutation or phenotype group and the number that are
affected by pancreatitis. Assuming that 50% of all first degree relatives are mutation carriers, the result can be doubled to give an
estimate of penetrance in each group.
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was not signiﬁcantly different from any of the other four groups
if tested with the ManneWhitney U test (p¼0.06 to 0.8, going
from right to left in ﬁgure 3).
DISCUSSION
p.A16V has mainly been described in idiopathic pancreatitis,8 11 17
but this study shows that it can also have a phenotype consistent
with both HP and a compound recessive disease. EUROPAC has
traditionally recruited individuals with a family history indi-
cating a genetic predisposition to pancreatitis, prior to any
genetic testing. This approach did not prove adequate to char-
acterise p.A16V. To produce this publication, active recruitment
was required from Europe and elsewhere, to identify and recruit
any individual with a p.A16V mutation. This in itself indicates
the distinct nature of this particular PRSS1 mutation. As stated
previously, p.A16V was initially reported in children with idio-
pathic pancreatitis. The low rate of genetic testing in idiopathic
pancreatitis makes the exact incidence in this group difﬁcult to
fully characterise. There is inherent age related bias as genetic
testing is more likely to be indicated in younger patients. Overall,
it is unlikely that clinical testing would be cost effective, even in
the young.
The low number of p.A16V families, combined with the
different referral pattern for this mutation, makes comparison of
disease severity between p.A16V and the other mutations difﬁ-
cult. In previous papers, hierarchical analysis has been used to
allow for family structure2; this is clearly not possible with the
small number of p.A16V families. Relatively simplistic statistical
approaches have therefore been adopted and this must be taken
into account when considering the results. Nevertheless, the
great variability in penetrance for this mutation is self evident.
This is suggestive of a multi-gene effect, whereas there is no
evidence against simple autosomal dominant aetiology with
either p.R122H or p.N29I. Such multigene dependence may
explain the trends seen for both later onset of pancreatitis and
diabetes.
Mechanistically, p.R122H and p.N29I have both been linked
to either increased auto-activation of cationic trypsinogen or
reduced deactivation.18 19 Phenotypically, p.R122H and p.N29I
are very similar, although p.R122H results in a slightly earlier age
of onset as described here and as reported previously.2 p.A16V
affects the very ﬁrst amino acid of mature trypsinogen, lying at
the edge of the signal peptide, although not forming a part of it.
It has therefore previously been considered to inﬂuence
secretion.11
It is tempting to assume that a secretion defect is inadequate
to cause pancreatitis without some other factor (genetic or
environmental), hence the difference in phenotype. However,
secretion failure is considered to explain the link between the p.
R116C mutation of PRSS1 and pancreatitis and this mutation
has thus far only been linked to autosomal dominant disease,20
and furthermore the latest data indicate that the p.A16V mutant
is actually secreted normally.20 Other work has established that
p.A16V increases the rate of chymotrypsinogen C (CTRC) acti-
vation of trypsinogen by approximately fourfold. This results in
accelerated trypsinogen activation in vitro, possibly explaining
the link with pancreatitis.21 How this would explain the features
of p.A16V penetrance is unclear.
Some families do appear to have a phenotype consistent with
HP. This suggests relatively common polymorphisms in modiﬁer
genes within the populations that contribute to these families,
although it is also possible that this is explained by a shared
environment. One family has highly aggressive disease restricted
to a single generation, suggesting a ‘jackpot’ combination of the
p.A16Vmutation from one side of the family and polymorphisms
in modiﬁer genes from the other. Relatively few families were
identiﬁed with single cases of pancreatitis, but it is likely that
a higher proportion of such families go unreported. Penetrance in
such families may require speciﬁc environmental exposures.
These data suggest that the clinical signiﬁcance of identifying
a p.A16V mutation for the patient and their family is context
dependent. A mutation in a family with a history of pancreatitis
must be considered as an indication that other members of the
family are at risk and that further testing within the family will
identify individuals who will beneﬁt from clinical vigilance. This
may be reﬁned by characterisation of the inheritance pattern and
concentrating mutation screening on those most likely to be
affected, siblings if all cases to date have been in a single gener-
ation or children if there is apparent autosomal dominant
inheritance. In contrast, a mutation in an individual with
apparently sporadic disease will tell us very little about the risk to
other members of the family and at best this will be a partial
explanation of the patient’s condition.
There is obvious bias in our cohort of idiopathic patients, but
even so only two out of 141 apparently idiopathic patients
registered with EUROPAC had a p.A16V mutation, so testing of
idiopathic patients will have little chance of identifying
a mutation and will have only marginal beneﬁt for the patient.
At its most extreme, clinical vigilance may extend beyond
pancreatitis and its immediate complications to concern about
pancreatic cancer risk. It remains very difﬁcult to quantify this
risk. The best advice at present would be to consider individuals
on the basis of their family history regardless of the p.A16V
mutation status; if the family appears to have HP, the family
should be considered as having the cancer risk associated
with HP and if the pancreatitis appears to be sporadic, then the
cancer risk should be considered equivalent to any other idio-
pathic case.
Figure 3 An estimate of penetrance in different mutation groups.
Penetrance for individual families is estimated by doubling the proportion
of affected first degree relatives of index cases. This assumes that 50% of
first degree relatives of the index case are mutation carriers. Results of
actual mutation analysis and knowledge of off kindred relationships were
ignored in this calculation. The box plot shows the inter-quartile range
(box) and the range (whiskers). The indented region indicates the 95% CI
for the median (marked with a horizontal line). KruskaleWallis testing of
the medians showed a significant difference across the five groups with
a p value of 0.02. HP, hereditary pancreatitis.
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